Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Spinal cord tumours (intramedullary and intradural), drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Almost no trial evidence; treatment is extrapolated from brain tumours and case series.
Infiltrating cord astrocytomas cannot be removed and have no effective drug.
Radiotherapy to the cord is limited by myelopathy risk.
Neurological deficit at presentation, not treatment, decides most outcomes, so diagnosis is often too late.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Belzutifan, the HIF-2 alpha inhibitor approved for VHL-associated central nervous system haemangioblastomas, with surveillance imaging.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Haemangioblastoma of the cord and cerebellum recognised as a hallmark of the syndrome.
A milestone in how this cancer is treated.